Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PNT2258

Known as: DNA Interference Oligonucleotide PNT2258 
A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

PNT100

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Unintended target effect of anti-BCL-2 DNAi
INTRODUCTION Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Design of a phase I clinical trial with PNT2258, a novel DNA interference oligonucleotide (DNAi), in patients with advanced solid tumors.
TPS3110 Background: With the knowledge that Bcl-2 facilitates drug resistance and cell survival, a DNA interference (DNAi… Expand
Is this relevant?
2016
2016
PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
Current therapy for BCL-2-associated tumors such as Non-Hodgkin Lymphomas (NHL) is inadequate. The DNAi PNT2258, a 24 base single… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
TPS7577Background: PNT2258, a liposomal encapsulated DNA interference (DNAi) oligonucleotide nanoparticle targeting the BCL2… Expand
Is this relevant?
2014
2014
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.
2586 Background: PNT2258 contains PNT100, a DNA interference (DNAi) oligonucleotide encapsulated in a lipid nanoparticle. PNT2258… Expand
Is this relevant?
2013
2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
PurposeMaximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
Background Aberrant BCL2 control mechanisms are a defining characteristic of a variety of cancers including follicular lymphoma… Expand
Is this relevant?
2013
2013
Abstract 3529: Effect of PNT2258, an anti-BCL2 DNA-interference drug, on tumor growth and immunological markers in mice and humans.
Background: The dysregulation of apoptosis is a defining characteristic of malignant cells where excessive concentration of BCL2… Expand
Is this relevant?
2012
2012
Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Bcl-2 and bcl-XL are anti-apoptotic proteins that… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE